GordonMD Global Investments is a biopharmaceutical investment firm managing both private and public funds. Founded in 2021, the firm focuses on differentiated investment opportunities in the biopharmaceutical sector, leveraging its unique combination of medical expertise and investing acumen to create an advantage for investors.
The firm's portfolio includes notable companies such as Antios Therapeutics, Flare Therapeutics, and Taysha Gene Therapies. Founded by Craig Gordon, MD, a licensed physician with over 10 years of buy-side experience in global biopharmaceutical portfolios, GordonMD Global Investments primarily invests in Series A and Series B rounds, with occasional participation in post-IPO equity rounds.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.